Kainic acid, an analogue of the excitatory neurotransmitter glutamate, can trigger seizures and neurotoxicity in the hippocampus and other limbic structures in a manner that mirrors the neuropathology of human temporal lobe epilepsy (TLE). However, the underlying mechanisms associated with the neurotoxicity remain unclear. Since amyloid-b (Ab) peptides, which are critical in the development of Alzheimer's disease, can mediate toxicity by activating glutamatergic NMDA receptors, it is likely that the enhanced glutamatergic transmission that renders hippocampal neurons vulnerable to kainic acid treatment may involve Ab peptides. Thus, we seek to establish what role Ab plays in kainic acid-induced toxicity using in vivo and in vitro paradigms. Our results show that systemic injection of kainic acid to adult rats triggers seizures, gliosis and loss of hippocampal neurons, along with increased levels/processing of amyloid precursor protein (APP), resulting in the enhanced production of Ab-related peptides. The changes in APP levels/processing were evident primarily in activated astrocytes, implying a role for astrocytic Ab in kainic acid-induced toxicity. Accordingly, we showed that treating rat primary cultured astrocytes with kainic acid can lead to increased Ab production/secretion without any compromise in cell viability. Additionally, we revealed that kainic acid reduces neuronal viability more in neuronal/astrocyte co-cultures than in pure neuronal culture, and this is attenuated by precluding Ab production. Collectively, these results indicate that increased production/secretion of Ab-related peptides from activated astrocytes can contribute to neurotoxicity in kainic acid-treated rats. Since kainic acid administration can lead to neuropathological changes resembling TLE, it is likely that APP/Ab peptides derived from astrocytes may have a role in TLE pathogenesis.
INTRODUCTION
Kainic acid, an analogue of the excitatory neurotransmitter glutamate, can induce seizures in adult rats originating from the CA3 region of the hippocampus and then spreading to other limbic structures. The epileptogenic effects of kainic acid are preeminently caused by the activation of ionotropic kainate receptors located on CA3 mossy fiber synapses. This triggers Ca 12 influxes into the cells, generating synchronized, network-driven glutamatergic currents which subsequently induce seizures and facilitate neurotoxicity (10, 44, 80) . The consequences of kainic acid administration include neuronal loss in CA1-CA3 regions, the reorganization of mossy fibers and gliosis; neuropathologies which resemble human temporal lobe epilepsy (TLE) (45, 89) . Glutamate, derived from both synaptic and nonsynaptic (ie, astrocytes) sources, plays a critical role in kainic acidinduced epilepsy, as its administration can induce seizures and loss of neurons in animals, which can be precluded by glutamate receptor antagonists (19, 22, 29) . Nevertheless, the cellular mechanisms by which kainic acid triggers cell death remain unclear as apoptotic, necrotic and autophagic markers are found to be altered in affected neurons (81, 82) . Thus, defining the signaling pathways that underlie neurotoxicity following kainic acid-induced seizure may provide a better understanding of the pathology associated with TLE.
Numerous studies have shown that amyloid b (Ab) peptides, produced constitutively in the normal brain, play a critical role in reducing neuronal viability and subsequent development of Alzheimer's disease (AD), the most common type of senile dementia affecting the elderly (21, 48) . These peptides are derived from the amyloid precursor protein (APP), which can be proteolytically processed either by non-amyloidogenic a-secretase or amyloidogenic bsecretase pathways. The a-secretase (eg, ADAM10) cleaves APP within the Ab domain, yielding soluble N-terminal APPa (sAPPa) and a C-terminal fragment (a-CTF) that can be further processed by g-secretase to generate Ab /Ab fragments . The b-secretase cleaves APP to generate soluble APPb (sAPPb) and an Abcontaining C-terminal fragment (b-CTF), which is processed via gsecretase to yield full-length Ab 1-40 /Ab 1-42 peptides. While bsecretase is an aspartyl protease called b-site APP cleaving enzyme (BACE1), g-secretase comprises the aspartyl protease presenilin 1/2 (PS1/PS2) and three cofactors, that is, nicastrin, presenilin enhancer 2 (PEN2) and anterior pharynx defective 1 (APH1) (3, 28) .
There is now considerable evidence suggesting that toxicity induced by Ab-related peptides is partly mediated by glutamate, as transient inactivation and/or blockade of the NMDA receptor by antagonists can protect neurons against Ab toxicity (1, 40, 75, 78, 85) . These results raise the possibility that enhanced glutamatergic activity that renders hippocampal neurons vulnerable to excitotoxicity in animal models of TLE (50, 67, 82) may involve Ab peptides. This is supported by three lines of evidence (i) prolonged activation of glutamatergic NMDA receptors can enhance amyloidogenic processing of APP (13, 43, 64) , (ii) neuronal vulnerability to excitotoxicity is enhanced in the presence of Ab (53) and (iii) transgenic mice overexpressing Ab exhibit spontaneous seizures or decreased threshold to seizures compared to wild-type mice (20, 58, 87) . Nevertheless, little is known regarding the involvement of Ab peptides in the loss of neurons following kainic acid-induced toxicity. To address this issue, we evaluated alterations in the levels/distribution and processing of APP in the hippocampus of kainic acid-treated rats. In parallel, using rat hippocampal neuronal and mixed hippocampal neuronal/astrocyte cultures, we determined the significance of Ab peptides in kainic acid-mediated neurotoxicity. Collectively, our results reveal that increased levels of astrocyte-derived Ab peptides have a role in reducing neuronal viability in the kainic acid model of TLE.
MATERIALS AND METHODS

Materials
Polyacrylamide electrophoresis gels (4%-20%), cell culture reagents such as Hank's balanced salt solution, fetal bovine serum, Neurobasal media, B27 and N2 supplements, and ELISA kits for the detection of rat Ab and Ab were purchased from Invitrogen (Burlington, ON, Canada), whereas the enhanced chemiluminescence kit (ECL) and the bicinchoninic acid (BCA) protein assay kit were from Thermo Fisher Scientific (Montreal, QC, Canada). Kainic acid, g-secretase inhibitors (DAPT and L-685,458) and 3-(4,5-dimethylthiozolyl)-2,5-diphenyltetrazolium bromide (MTT) were obtained from Sigma-Aldrich (Oakville, ON, Canada). Human and rat Ab and the reverse sequence Ab 42-1 were purchased from American Peptides (Sunnyvale, CA, USA) and the Live/Dead cell viability assay kit was from Molecular Probes (Eugene, OR, USA). Fluoro-Jade C was from Chemicon Int., (Temecula, CA, USA), whereas b-secretase BACE1 activity assay kit was from Abcam (Cambridge, United Kingdom). Sources of all primary antibodies used in the study are listed in Table 1 . All horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology (Paso Robles, CA, USA). Vivaspin filtration columns were from GE Healthcare Ltd. (Mississauga, ON, Canada), whereas protease inhibitor cocktail, BACE1 inhibitor BIV and fluorogenic g-secretase substrate were from Calbiochem (San Diego, CA, USA). All other chemicals were from either Sigma-Aldrich or Thermo Fisher Scientific.
Systemic administration of kainic acid
Adult male Sprague-Dawley rats obtained from Charles River (St Constant, QC, Canada) were housed with access to food and water ad libitum. The experiments were performed in accordance with Institutional and Canadian Council on Animal Care guidelines. Adult rats were injected intraperitoneally with either kainic acid dissolved in normal saline (12 mg/kg) or equal volume (0.2-0.25 mL) normal saline as described previously (8, 79) . Following treatment, the control and kainic acid-treated rats were euthanized at 12 h, 2, and 12 days by decapitation; their hippocampi were dissected out of the brain and frozen immediately in dry-ice for biochemical assays. For histological studies, control and kainic acidtreated rats were anesthetized with 8% chloral hydrate and then perfused with phosphate-buffered saline (PBS), followed by 4% paraformaldehyde (PFA). Brains were sectioned (20 or 40 mm) on a cryostat and collected in a free-floating manner for further processing.
Fluoro-Jade C Staining
Fluoro-Jade C labels degenerating neurons, dendrites and axons (68) . Sections from control and kainic acid-treated rat brains from various time periods were stained with 0.0001% Fluoro-Jade C in 0.1% acetic acid as described earlier (38) .
Immunostaining
Brain sections from control and kainic acid-treated rats (3-5 animals/group) were processed as described earlier (38) . For the enzyme-linked procedure, 40 lm sections were incubated overnight at 48C with anti-APP (CTM1), anti-BACE1, anti-PS1, antinicastrin, anti-PEN2 or anti-APH1 antiserum at dilutions listed in Table 1 . Sections were then exposed to HRP-conjugated secondary antibodies for 1 h and developed using the glucose-oxidase-nickel enhancement method. For double immunofluorescence staining, brain sections (20 lm) from control and kainic acid-treated rats were sequentially labeled with anti-APP (CTM1), anti-BACE1, anti-PS1, anti-nicastrin, anti-PEN2 or anti-APH1 antisera, followed by anti-ED1, anti-glial fibrillary acidic protein (GFAP) or anticleaved caspase-3 antisera at dilutions listed in Table 1 . The primary antibodies were labeled with either Texas Red-or FITCconjugated secondary antibodies (1:200), washed and then mounted with Vectashield medium. Immunostained sections were examined and photographed using a Zeiss Axioskop-2 fluorescence microscope (49) .
Immunoblotting
Hippocampal tissues from control and kainic acid-treated rats from different time periods (6-8 animals/group) were homogenized in ice-cold radioimmunoprecipitation assay-lysis buffer and protein content was determined using a BCA kit. The proteins were separated by electrophoresis on 4%-20% polyacrylamide gels and then transferred to nitrocellulose membranes. The membranes were blocked with 5% non-fat milk and incubated overnight at 48C with anti-APP (369), anti-BACE1, anti-PS1, anti-nicastrin, anti-PEN2, anti-APH1, anti-sAPPa, anti-sAPPb, anti-Y1888, anti-extracellular signal-regulated kinases 1/2 (ERK1/2), anti-phospho-cAMP response element-binding protein (phospho-CREB), anti-a-fodrin, anti-m-calpain and anti-cleaved caspase-3 antibodies at dilutions listed in Table 1 . Membranes were then incubated with the HRPconjugated secondary antibodies and developed using an ECL detection kit. Membranes were subsequently reprobed with either anti-b-actin or anti-total ERK1/2 antibody and immunoreactive proteins were quantified using MCID image analysis system (37).
b-and c-secretase activity assays
The b-secretase activity in the hippocampus of control and kainic acid-treated rats (4-6 animals/group) was measured using the fluorometric b-secretase activity assay kit according to the manufacturer's instructions as described earlier (83) . The fluorescence was measured at excitation wavelength of 355 nm and emission wavelength of 495 nm and specific activity of the enzyme was determined by incubating parallel samples with a b-secretase inhibitor BIV. The g-secretase activity assay was performed (4-6 animals/ group) as described previously (49) . The fluorescence was measured at an excitation wavelength of 355 nm and emission wavelength of 440 nm at 378C and the specific activity was determined by incubating a parallel set of samples with 100 lM g-secretase inhibitor L-658,458. All samples were assayed in duplicate and data were obtained from three independent experiments.
Rat Ab and Ab 1-42 levels
Ab peptides from hippocampus of control and kainic acid-treated rats (4-6 animals/group) were solubilized in 5M guanidine buffer (16) , centrifuged and then assayed for rat Ab or Ab 1-42 levels using ELISA kits as described earlier (49) . In a separate series of experiments, cellular and secretory levels of Ab and Ab were measured in cultured astrocytes treated with or without kainic acid in a similar manner. All samples were assayed in duplicate and the data were obtained from three independent experiments.
Primary hippocampal neuronal, astrocyte and astrocyte/neuronal cultures
Primary rat hippocampal neuronal cultures were prepared from 17/ 18-day-old embryos of time-pregnant Sprague-Dawley rats as described previously (86, 96) . In brief, the hippocampal region was dissected in Hanks balanced salt solution supplemented with 100 mM HEPES, 10 mM Na-pyruvate, 50 mM L-glutamine, 10 U/mL penicillin and 10 mg/mL streptomycin and digested with 0.25% trypsin/EDTA. The cell suspension was filtered through a cell strainer and then plated on either 96-well plate or 12 mm glass coverslips. The cultures were grown at 378C in a 5% CO 2 -humidified atmosphere in Neurobasal medium supplemented with B27, 50 mM L-glutamine, 100 mM HEPES, 10 mM Na-pyruvate, 10 U/mL penicillin and 10 mg/mL streptomycin, and 1% FBS. The medium was replaced 1 day later without FBS and all experiments were performed on day 6 after plating. Primary rat hippocampal astrocytes (Sciencell, CA, USA) were seeded on Poly-D-lysine-coated plates and grown in the associated astrocyte media at 378C as per the manufacturer's instructions. Cells were grown to confluency and passaged using TrypLE Express. To prepare astrocyte-neuronal cocultures, hippocampal neurons were prepared as described above, and then seeded directly on a layer of astrocytes grown to confluency. Media conditions for co-cultures follow the protocol for neuronal culture and all experiments were performed 6 days following cell plating.
Treatment of cultured neurons, astrocytes and mixed neurons/astrocytes
The oligomeric forms of rat and human Ab 1-42 used in all experiments related to toxicity were prepared as described earlier (75) and added to neurons to the final concentrations (0.01-20 mM) for different periods of time (ie, 12, 24, 48 or 72 h). Control and Abtreated cultures were then processed for MTT cell viability and live/dead cell toxicity assays (75) . In a separate set of experiments, cultured rat hippocampal astrocytes were treated with or without 20 mM g-secretase inhibitor DAPT for 24 h and then exposed to 100 mM kainic acid for an additional 24 h. Subsequently, the cellular and secretory levels of rat Ab 1-40 /Ab 1-42 as well as cell viability were measured. In parallel, cultured neurons and mixed neurons/ astrocytes were exposed to 100 mM kainic acid with or without 20 mM DAPT for 24 or 48 h and their cell viability was assessed (49) .
Cell viability assays
Viability of neurons or astrocytes was assessed using the cell proliferation colorimetric MTT assay (83) . Control and treated culture plates were replaced with new medium containing 0.25% MTT and then incubated for 2 h at 378C. The reaction was terminated and measured spectrophotometrically at 570 nm. Neuronal viability following treatment with Ab peptide was also assessed using the Live/Dead assay kit containing calcein AM and ethidium homodimer (EthD-1) as the fluorescent probes. Control and treated cultured neurons were incubated with medium containing 2 mM calcein AM and 4 mM EthD-1 for 30 min at 378C, fixed in 4% PFA and then visualized under a Zeiss Axioskop-2 fluorescent microscope (75) .
Statistical analysis
Data are expressed as means 6 SEM. Statistical significance of differences was determined by one-way ANOVA followed by Newman-Keuls post hoc analysis for multiple comparisons or unpaired two-tailed Student's t test for single comparison with a significance threshold of P < 0.05. All analyses were performed using GraphPad Prism Software.
RESULTS
Loss of neurons and proliferation of glial cells in kainic acid-treated rats
In keeping with earlier studies (8, 10, 45, 80) , we observed that systemic administration of kainic acid evoked seizures characterized by rearing and falling, facial and forelimb clonus, and "wet-dog" shakes that lasted about 8-10 h. After a seizure-free period lasting a few days, a high proportion of animals surviving such an attack exhibited a chronic phase of spontaneous recurrent limbic seizures with no remission over 12 days of the experimental paradigm (18, 89) . These behavioral changes are accompanied by a loss of neurons, as apparent by Fluoro-Jade C and cleaved caspase-3-labeling, as well as glial hypertrophy in the hippocampus of the rat brain ( Figure 1A-K) . As expected, reduced neuronal viability progressed with time primarily in CA1-CA3 pyramidal cells and the hilar region of the dentate gyrus, whereas the granule cell layer was relatively spared (8, 80, 84) . The hypertrophy of astrocytes and microglia (data not shown) was apparent to some extent at 12 h and then gradually increased over 12 days post-treatment period (19, 35, 80) ( Figure 1A-I) . The progressive loss of neurons and activation of glial cells were seen in the hippocampi of both hemispheres in kainic acid-treated rats. Earlier studies have indicated that kainic acid induces neurotoxicity by increasing Ca 12 influx, the production of reactive oxygen species and the activation of multiple downstream signaling cascades including mitogen activated protein (MAP) kinase and the cysteine protease calpain (4, 10, 11, 34, 80, 82, 93) . While calpain exists in two different isoforms (m-and m-calpains), the family of MAP kinase is composed of various enzymes such as stressactivated protein kinases and ERK1/2 (34, 80, 93) . A significant induction of phospho-ERK1/2 and its downstream substrate phospho-CREB was evident following kainic acid administration at 12 h and 2 days, respectively, and remained elevated over the 12 day post-treatment period ( Figure 2A ). Concurrently, we also observed a protracted increase in calpain levels in the hippocampus of kainic acid-treated rats. To validate the activation of calpain, we measured the breakdown products of non-erythroid aII-spectrin (ie, fodrin)-a signature downstream substrate which yields unique proteolytic fragments following cleavage by caspase and calpain (4, 11, 82) . While calpain-specific 150/145kD aII-spectrin breakdown products (SBDP) were increased at all time points following administration of kainic acid, with maximal changes apparent at 2 day post-treatment, caspase-3 specific 120 kD SBDP showed alterations mostly at 2 day post-treatment over the 12 days experimental paradigm ( Figure 2B ). Caspase activation is further supported by our Western blot ( Figure 2B ) and the detection of immunoreactive cleaved-caspase-3-positive neurons ( Figure 1J ,K) in kainic acidtreated rat hippocampus compared to control rats.
Increased levels and expression of APP and its processing enzymes in kainic acid-treated rats APP levels were markedly increased at 2 and 12 days, but not at 12 h, following kainic acid administration compared to control rats ( Figure 3A) . At the cellular level, APP immunoreactivity in the control hippocampus was evident mostly in CA1-CA3 pyramidal neurons and granule cells of the dentate gyrus but not in glial cells (Figure 4A ,B; Supporting Information Figure  S1A -D). Occasionally, APP-immunoreactive neurons were also apparent in the hilus region of the dentate gyrus ( Figure 4A ). While the overall expression of APP decreased with time in the degenerating hippocampal neurons, a number of glial cells were found to express APP from 2 days onwards after kainic acid treatment ( Figure 4C -F). Our double labeling showed that immunoreactive APP is evident in a subset of GFAP-labeled reactive astrocytes, but not ED1-labeled activated microglia, following kainic acid treatment ( Figure 4G -J).
To determine if enhanced APP levels in kainic acid-treated rats were accompanied by a parallel increase in APP processing via the b-secretase pathway, we measured the levels/expression of BACE1 and four components of the g-secretase complex ( Figures 3B, Figures 5-6 ; Supporting Information Figures S1-S5) in the hippocampus of treated and control rats. We observed a significant increase in BACE1 levels at 2 and 12 days following kainic acid treatment compared to control rats ( Figure 3B ).
The components of the g-secretase complex, PS1 ( Figure 3C ), nicastrin ( Figure 3D ), PEN2 ( Figure 3E ) and APH1 ( Figure 3F ) were likewise found to be enhanced in kainic acid-treated rats. Consistent with earlier studies (37, 71) , immunoreactive BACE1 and four components of g-secretase complex were evident mostly in neurons of the normal brain. In the hippocampal region, intense immunoreactivity for BACE1 ( Figure. Figures 4A,B and S5I-L) was apparent in the CA1-CA3 pyramidal cell layer and in a few medium-sized neurons scattered in the strata oriens and stratum radiatum but not in glial cells. Within the dentate gyrus, granule cell somata were outlined by a fine mesh of weakly stained puncta and occasional strongly labeled neurons. In comparison with the control hippocampus, a number of glial cells were found to express immunoreactive BACE1 ( Figure 5C-F) and components of g-secretase complex in kainic acid-treated rats from 2 day post-treatment onwards (Figure 6C-F; Supporting Information Fig. S2C -F, S3C-F and S4C-F). Our double immunolabeling revealed that a subset of reactive astrocytes express immunoreactive BACE1 ( Figure  5G ,H), PS1 (Fig. 6G, H) , nicastrin (Supporting Information Figure S2G,H) , PEN2 (Supporting Information Figure S3G ,H) and APH1 (Supporting Information Figure S4G ,H) in the hippocampus of treated rats. Activated microglia, conversely, did not express either BACE1 (Figure 5I,J) or components of gsecretase, that is, PS1 (Figure 6I,J) , nicastrin (Supporting Information Figure S2I ,J), PEN2 (Supporting Information Figure  S3I ,J) and APH1 (Supporting Information Figure S4I ,J) at any time points following kainic acid administration.
APP processing and enhanced rat Ab 1-40 /Ab 1-42 levels in kainic acid-treated rats
To determine whether kainic acid treatment can influence APP processing, we first measured the activity of b-and g-secretases, as well as the steady state levels of APP-cleaved products (sAPPa, sAPPb, a-CTF and b-CTF) in the hippocampus of treated and control rats. Our results showed that BACE1 and g-secretase activities were significantly increased in time-dependent manner following kainic acid administration ( Figure 7A,B) . Accompanying these data, levels of sAPPb were increased from 2 day post-treatment, while sAPPa levels were not altered at any time relative to the control rats ( Figure 7C ). The levels of a-CTF and b-CTF were also significantly increased after kainic acid treatment, but the changes observed for b-CTF were found to be somewhat higher than a-CTF ( Figure 7D ). In parallel, rat Ab 1-40 and Ab 1-42 levels, as detected by ELISA, were markedly increased from 2 day onwards in the hippocampus of kainic acid-treated rats compared to control rats ( Figure. 7E,F) .
Rat Ab 1-42 is toxic to primary rat hippocampal neurons
Consistent with earlier results (39, 75) , chronic exposure to oligomeric human Ab 1-42 reduced viability of hippocampal neurons in a concentration-dependent manner, as evident by a reduction in MTT values (Supporting Information Figure S6A ). To determine whether rat Ab , which differs from the human Ab 1-42 by three amino acids (15) , is toxic to cells, we first evaluated its dose-dependent (1-20 mM) effect on hippocampal neurons. The viability of neurons, as indicated by MTT assay, was not affected by rat 1-10 mM Ab , but significantly decreased with 20 mM Ab 1-42 following 24 h treatment (Supporting Information Figure S6B ). The toxic potency of rat Ab was further substantiated by a timedependent decrease in MTT value, with 50% cell death observed at 72 h post-treatment (Supporting Information Figure S6C ). Our live-dead assay also showed an increase in the number of dead cells following exposure to 20 mM rat Ab 1-42 for 24 h (Supporting Information Figure S6D -G).
Kainic acid treatment enhanced Ab 1-40 /Ab 1-42 levels in cultured rat astrocytes Our in vivo studies indicated that kainic acid-induced neurotoxicity was accompanied by increased levels/processing of APP, Figure 2 . A. Histogram and representative immunoblots showing the levels of phospho-ERK1/2, total ERK, phospho-CREB in the hippocampus of control and kainic acid-treated rats. Note the relative increase in the levels of these markers following treatment with kainic acid compared to saline-treated control rats. B. Histogram and representative immunoblots showing the levels of m-calpain, fodrin, caspase 3 in the hippocampus of control and kainic acid-treated rats. Note the relative increase in the levels of these markers following treatment with kainic acid compared to saline-treated control rats. All blots were reprobed with anti-b-actin to monitor protein loading. Values represent means6SEM from 6-8 rats. *P < 0.05, **P < 0.01.
leading to the enhanced production of Ab-related peptides. Since expression of APP and its processing enzymes were increased in a subset of reactive astrocytes, it is likely that Ab peptides are partly generated from these astrocytes. To validate this notion, rat primary astrocytes were treated with 100 mM kainic acid for different durations (12 h-48 h) and then cellular/ secretory Ab levels were measured using ELISA. Our results showed that cellular levels of Ab were significantly increased at 12 h and 24 h, whereas Ab were increased only at 12 h after kainic acid treatment ( Figure 8A ). However, Note the time-dependent increase in the levels of APP, BACE1 and four components of the g-secretase complex following treatment with kainic acid compared to saline-treated control rats. All blots were reprobed with anti-b-actin to monitor protein loading. Values represent means6SEM from 6-8 rats. *P < 0.05, **P < 0.01, ***P < 0.001. secretory levels of Ab and Ab 1-42 were markedly increased with time following exposure to 100 mM kainic acid ( Figure 8B ). Pre-treatment with the g-secretase inhibitor DAPT attenuated enhanced levels of Ab peptides, suggesting that an increased production/secretion of the peptides is triggered by kainic acid treatment ( Figure 8C ). In parallel, we observed that the viability of cultured astrocytes was not compromised after 48 h exposure to either 100 mM kainic acid or 20 mM DAPT ( Figure 8D ).
Kainic acid-induced toxicity of mixed neuron/ astrocyte cultures protected by c-secretase inhibitor
To determine the significance of Ab peptides in kainic acid-induced toxicity, pure rat hippocampal cultured neurons were first exposed to kainic acid (50-200 mM) for either 24 or 48 h, and then cell viability was assessed using MTT assay. As expected, viability of neurons was reduced significantly in most conditions, but it did not exhibit marked variation with either increasing concentrations or time following exposure to kainic acid ( Figure 8E ). Interestingly, treating mixed neuron/astrocyte co-cultures with 100 mM kainic acid for 24 h was found to reduce cell viability significantly more than what was observed with pure neuronal cultures ( Figure 8F ). Since kainic acid did not affect the viability of cultured astrocytes ( Figure 8D ), we wanted to establish if Ab peptides generated from cultured astrocytes in response to this treatment may be involved in triggering neurotoxicity. Thus, we pretreated mixed neuron/astrocyte co-cultures with or without 20 mM DAPT, and then exposed them to 100 mM kainic acid for 24 h. Our results clearly showed that DAPT treatment can attenuate kainic acid-induced toxicity (Figure 8G) , indicating a role for Ab peptides in reducing viability of neurons. 
DISCUSSION
This study uses a combination of experimental approaches to show that increased production and levels of Ab peptides in reactive astrocytes have a role in neurotoxicity triggered by the systemic administration of kainic acid. This is supported by data which show that (i) kainic acid-induced loss of hippocampal neurons is associated with higher expression of APP, BACE1 and g-secretase components in a subset of activated astrocytes, (ii) activity of b-and g-secretases are enhanced along with the levels of APP-cleaved products including Ab and Ab in the hippocampus of kainic acid-treated rats, (iii) rat Ab , like human Ab , is toxic to cultured hippocampal neurons, (iv) exposing rat cultured astrocytes to kainic acid can lead to enhanced production/secretion of Ab 1-40 /Ab 1-42 without compromising their viability and (v) loss of rat cultured hippocampal neurons by kainic acid is enhanced in the presence of astrocytes, and can be attenuated by the g-secretase inhibitor DAPT. Collectively, these results suggest that activated astrocytes, by way of heightened APP expression and the increased production of Ab peptides, play a critical role in reducing viability of neurons triggered by kainic acid. Since kainic acid treatment can lead to neuropathological changes resembling those observed in human TLE, it is possible that APP/Ab peptides derived from astrocytes may also have a role in TLE pathogenesis. Histograms showing the activity of b-(A) and g-(B) secretases in the hippocampus of control and kainic acid-treated rats. Note the relative increase in the activity of both secretases following systemic administration of kainic acid compared to control rats. C and D. Representative immunoblots and histograms showing levels of sAPPa and sAPPb (C), a-CTF and b-CTF (D) in the hippocampus of control and kainic acid-treated rats. Note the relative increase in the levels of sAPPb, a-CTF and b-CTF, but not sAPPa, following administration of kainic acid compared to control rats. E and F. Histograms showing the quantification of rat Ab 1-40 (E) and Ab 1-42 (F), as detected by ELISA, in the hippocampus of control and kainic acidtreated rats. Note the significant increase in the levels of both Ab peptides following kainic acid administration compared to control rats. All blots were re-probed with anti-b-actin to monitor protein loading. Values represent means6SEM from 4-8 rats. *P < 0.05, **P < 0.01, ***P < 0.001.
Loss of neurons in kainic acid-treated rats
Consistent with earlier studies, we observed that systemic administration of kainic acid can induce loss of neurons, along with glial hypertrophy and proliferation in the hippocampus (8, 45, 80, 84) . These effects are largely mediated by kainate receptor-induced glutamatergic currents that trigger an influx of Ca 12 and subsequent Histogram depicting the levels of Ab in primary rat astrocyte cultures treated with either kainic acid, g-secretase inhibitor DAPT, or a combination of the two (DAPT 1 KA) relative to control. Note that DAPT drastically reverses the increase in Ab 1-40 levels triggered by kainic acid and this effect is especially prominent in the conditioned media. D. Histogram showing no change in the viability of cultured astrocytes following treatment with kainic acid, DAPT or DAPT 1 kainic acid, as measured by an MTT assay. E. Histogram showing the effect of kainic acid on the viability of rat primary hippocampal cultured neurons as assessed by an MTT assay. Kainic acid was found to be toxic to neurons in relation to control. F. Histogram showing viability of kainic acid-treated neuron/astrocyte co-cultures and pure neuronal cultures compared to control. G. Histogram showing the viability of neuron/astrocyte co-cultures in relation to control following treatment with kainic acid, DAPT and DAPT 1 kainic acid. Kainic acid-induced death of neurons was attenuated by DAPT pretreatment. All cultured data represent means6SEM from 3-4 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
activation of downstream signaling cascades including ERK1/2, calpain and caspase as observed in the present study (4, 10, 34, 82, 93) . Since neuronal vulnerability to excitotoxicity can be enhanced by Ab peptides (53) , and glutamate receptor activation can regulate amyloidogeneic processing of APP (13, 43, 64) , it is of critical relevance to determine if Ab peptides may have a role in reducing viability of neurons following kainic acid administration. This will not only refine the molecular pathways associated with seizure-induced neuronal death mechanisms, but also may provide novel treatment targets for patients with TLE.
Influence of kainic acid administration on APP and its processing enzymes
Some earlier studies have shown that kainic acid can trigger APP expression (72, 91) , but its significance in the development of pathological features and/or loss of neurons remains unclear. The present study clearly demonstrates that systemic administration of kainic acid increases not only the levels of APP, but also the expression/levels as well as activity of both BACE1 and the gsecretase complex. These alterations, which appeared first at 2 days and increased following 12 days post-treatment, are accompanied by a time-dependent increase in APP cleaved intermediates including sAPPb and b-CTF, and most importantly, Ab and Ab peptides. Collectively, these results suggest that increased levels and amyloidogenic processing of APP may have a critical role in the development of TLE pathology. Interestingly, certain neurodevelopmental disorders such as Fragile X syndrome (FXS) and autism spectrum disorders (ASD), unlike TLE, have been shown to be associated with increase processing of APP via nonamyloidogenic pathway. While FXS is the most common form of inherited intellectual disability, ASD is characterized by persistent deficits in social communication/interactions and stereotypic repetitive behaviors (27, 88) . Brain abnormalities common to FXS and ASD include deranged cortical pyramidal dendritic spines and increased disruption of white as well as grey matters contributing to macrocephaly (32, 33, 60) . Pivotal work from two independent laboratories have demonstrated significantly elevated levels of sAPPa with a concomitant reduction in sAPPb and Ab levels in plasma and brain tissue samples of children with ASD (59, 60, 74) . Similarly, it has been shown that levels of APP and sAPPa are increased in the plasma as well as brain samples of individuals with FXS (60, 88) . Given the neurotrophic roles of sAPPa, it has been suggested that increased non-amyloidogenic processing of APP may result in macrocephaly associated with FXS and ASD, whereas enhanced processing of APP via amyloidogenic pathway may be associated with neurodegeneration observed in AD and TLE (41, 88) . Under normal conditions, APP, BACE1 and g-secretase components are usually localized in neurons of the brain, but not in glial cells (9, 37, 71, 76) . The present study showed that a subset of reactive astrocytes, which increased gradually with the progression of disease pathology (10, 25, 45, 90) , express APP and its processing enzymes in the hippocampus of kainic acid-treated rats. In fact, some earlier studies have reported that expression of APP, BACE1, PS1 and/or nicastrin can be induced in activated astrocytes of the brain following a variety of surgical/pathological lesions, such as cerebral ischemia, traumatic brain injury, excitotoxicity and cholesterol sequestration within the endosomal compartments (5, 7, 38, 54, 56, 72, 94) . There is also evidence that activated astrocytes located in proximity to Ab-containing neuritic plaques in AD brains and in mutant APP transgenic mice express higher levels of APP and/or its processing enzymes (31, 55, 63, 73) . Although the underlying mechanisms behind this occurrence remain unclear, it is possible that factors released from activated microglia or damaged neurons trigger astrocytic expression of APP and its processing enzymes (62) .
Role of Ab peptides in kainic acid-treated rats
The administration of Ab peptides has been implicated in the induction and propagation of seizures by possibly increasing extracellular glutamate levels caused by enhanced release and decreased uptake of glutamate (24, 36, 51, 66) . The present study clearly shows that kainic acid can trigger an increased production and secretion of Ab 1-40 /Ab 1-42 peptides, most likely in reactive astrocytes, which may partly be involved in the induction/propagation of seizures. In parallel, Ab peptides may also have a role in the kainic acid-driven loss of neurons. This is supported by three distinct lines of evidence-first, our results reveal that rat Ab peptides, as observed earlier (15), can be toxic to neurons. Second, we demonstrated that kainic acid treatment can enhance cellular/secretory levels of both Ab and Ab 1-42 from rat primary astrocytes without affecting their viability. Finally, using neuronal and neuronal/ astrocyte mixed cultures we showed that the presence of astrocytes exacerbates the neuronal toxicity of kainic acid, which can be ameliorated by pretreatment with the g-secretase inhibitor DAPT. Thus, increased levels of Ab derived from astrocytes may directly be involved in mediating toxicity induced by kainic acid. However, the underlying mechanism by which astrocytic Ab decreased neuronal vulnerability remains unclear. It is possible that Ab secreted from astrocytes following kainic acid treatment can act directly on neurons to decrease their vulnerability. Alternatively, Ab peptide secreted from kainic acid-treated astrocytes may act to increase the levels/processing of APP in neurons leading to enhanced intraneuronal Ab level (57) which can then decrease neuronal vulnerability.
Significance of Ab-related peptides in TLE
Although Ab-containing plaques and increased levels of APP are apparent in the brain of some TLE patients (26, 46, 69, 70) , the significance of these peptides in disease pathogenesis remain unclear. The predominant pathological feature associated with TLE is hippocampal sclerosis, which is characterized by atrophy, induration, gliosis, synaptic reorganization and loss of neurons in CA1, CA3 and the dentate hilar regions (12, 47, 77, 80) . There is evidence that excitotoxic glutamatergic transmission resulting from neuronal hyperactivity has a role in triggering recurrent seizures and death of neurons in the sclerotic hippocampus. More recently, a number of studies have shown that activated astrocytes, by regulating the uptake and release of glutamate, can directly contribute to the generation of seizures and loss of neurons in the hippocampus (17, 23, 25) . Our results, conversely, demonstrate that levels of Ab-related peptides, which increase gradually in kainic acid-treated rats may originate, at least in part, from a subset of activated astrocytes exhibiting enhanced expression of APP and its processing enzymes. Since Ab peptides can elevate extracellular glutamate levels by potentiating its release (36, 61, 66) and inhibiting its uptake by astrocytes (24, 30) , our data indicate a role for Ab in the development of seizures and subsequent loss of neurons in TLE brains. This is supported by the evidence that (i) Ab peptide can directly induce neuronal hyperexcitability and trigger epilepsy (51), (ii) transgenic mice overexpressing Ab peptide exhibit spontaneous as well as induced seizures more frequently than wild-type mice (20, 58, 87) , (iii) the prevalence of seizures is higher in AD cases than in control populations (2, 14, 42, 67 ) and the antiepileptic drugs can able to partially reverse AD-related pathology (6, 65, 92, 95) and (iv) kainic acid-induced neurotoxicity, as apparent from our results, can be attenuated by inhibition of Ab synthesis. Additionally, it is reported that immunization of mutant APP transgenic mice with Ab peptide protects them from seizures (52) . These results, taken together, not only highlight the significance of astrocytic Ab in TLE pathology, but also raise the possibility that lowering Ab levels may be beneficial in attenuating seizures and neurodegeneration.
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This work is supported by a grant from the Canadian Institutes of Health Research to SK. MM is a recipient of a studentship award from the Alberta Innovates -Health Solutions (AIHS). YW is a recipient of Doctoral Awards from Alzheimer Society of Canada and a Graduate Studentship Award from AIHS. We would like to indicate that none of the authors included in this manuscript has had any actual or potential conflict of interest including financial, personal or other relationships with other people or organizations at any time that could inappropriately influence the work. Figure S1 . A-L. Double immunofluorescence photomicrographs showing the localization of APP (A-D), BACE1 (E-H) and PS1 (I-L) with astrocyte marker GFAP and activated microglia marker ED1 in the hippocampal CA1 region of saline-treated control rats. Note the localization of APP, BACE1 and PS1 in neurons, GFAP in astrocytes but the absence of ED1 labeling due to lack of activated microglia in control brains. Scale bar, 100 mM. Figure S2 . A-F. Photomicrographs depicting cellular distribution of nicastrin in the hippocampus of saline-treated control (A, B) and following 12 h (C, D) and 12 day (E, F) kainic acidtreated rats at lower (A, C, E) and higher (B, D, F) magnifications. Note the expression of nicastrin in pyramidal and granule cell layers in control rats, whereas after 12 day kainic acid treatment nicastrin is evident mostly in glial cells of the hippocampus. G-J. Double immunofluorescence photomicrographs showing a subset of GFAP-labeled astrocytes (G, H), but not ED1-labeled microglia (I, J), exhibit immunoreactive nicastrin in 12 day kainic acid-treated rats. Py, pyramidal cell layer; DG, dentate gyrus. Scale bar, 100 mM. Figure S3 . A-F. Photomicrographs depicting cellular distribution of PEN2 in the hippocampus of saline-treated control (A, B) and following 12 h (C, D) and 12 day (E, F) kainic acidtreated rats at lower (A, C, E) and higher (B, D, F) magnifications. Note the expression of PEN2 in pyramidal and granule cell layers in control rats, whereas after 12day kainic acid treatment PEN2 is evident mostly in glial cells of the hippocampus. G-J. Double immunofluorescence photomicrographs showing a subset of GFAP-labeled astrocytes (G, H), but not ED1-labeled microglia (I, J), exhibit immunoreactive PEN2 in 12day kainic acid-treated rats. Py, pyramidal cell layer; DG, dentate gyrus. Scale bar, 100 mM. Figure S4 . A-F. Photomicrographs depicting cellular distribution of APH1 in the hippocampus of saline-treated control (A, B) and following 12hr (C, D) and 12day (E, F) kainic acidtreated rats at lower (A, C, E) and higher (B, D, F) magnifications. Note the expression of APH1 in pyramidal and granule cell layers in control rats, whereas after 12 day kainic acid treatment APH1 is evident mostly in glial cells of the hippocampus. G-J. Double immunofluorescence photomicrographs showing a subset of GFAP-labeled astrocytes (G, H), but not ED1-labeled microglia (I, J), exhibit immunoreactive APH1 in 12 day kainic acid-treated rats. Py, pyramidal cell layer; DG, dentate gyrus. Scale bar, 100 mM. Figure S5 . A-L. Double immunofluorescence photomicrographs showing the localization of nicastrin (A-D), PEN2 (E-H) and APH1 (I-L) with astrocyte marker GFAP and activated microglia marker ED1 in the hippocampal CA1 region of salinetreated control rats. Note the localization of nicastrin, PEN2 and APH1 in neurons, GFAP in astrocytes but the absence of ED1 labeling due to lack of activated microglia in control brains. Scale bar, 100 mM. MTT data presented as % of control (means 6 SEM) were obtained from 3-5 separate experiments, each performed in triplicate. Cont, control. * P < 0.05 and ** P < 0.001 compared to control value. Scale bar, 50 mm.
